Durability of Response in Patients With Chronic Plaque Psoriasis Treated With Certolizumab Pegol over 48 Weeks: Pooled Results from Ongoing Phase 3, Multicenter, Randomized, Placebo-Controlled Studies (CIMPASI-1, CIMPASI-2 and CIMPACT). J of Skin 2018, 2, S87. https://doi.org/10.25251/skin.2.supp.88.